Jointown Pharmaceutical Group Co Ltd
SSE:600998
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.58
5.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Jointown Pharmaceutical Group Co Ltd
Retained Earnings
Jointown Pharmaceutical Group Co Ltd
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Retained Earnings
ÂĄ16.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Retained Earnings
ÂĄ77.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Retained Earnings
ÂĄ42.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Retained Earnings
ÂĄ14.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
21%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Retained Earnings
ÂĄ19.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
24%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Retained Earnings
ÂĄ13.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
16%
|
|
Jointown Pharmaceutical Group Co Ltd
Glance View
In the sprawling landscape of the Chinese pharmaceutical industry, Jointown Pharmaceutical Group Co. Ltd. has emerged as a significant player, knitting together a vast network that facilitates the distribution of pharmaceutical products across the nation. Founded in 1999 and headquartered in Wuhan, Jointown has adeptly navigated the complexities of China's healthcare demands, becoming the country's largest privately-owned pharmaceutical wholesaler. The company’s operations span the procurement, distribution, and sale of a myriad of pharmaceutical products, medical devices, and healthcare supplies, effectively serving hospitals, clinics, and pharmacies through its extensive logistics and distribution channels. By leveraging cutting-edge technology to enhance its supply chain efficiency, Jointown ensures timely delivery and accessibility of medicines across urban and rural areas, thereby playing a pivotal role in supporting China's healthcare system. Jointown’s business model capitalizes on its robust logistical capabilities and comprehensive distribution network, which underpin its revenue streams. Through strategic partnerships with numerous domestic and international manufacturers, the company offers an impressive portfolio of pharmaceutical and healthcare products, maintaining a careful balance between proprietary and third-party offerings. This diversity in product offerings not only stabilizes its revenue base but also positions Jointown favorably in a highly competitive market. By continually expanding its e-commerce platforms and digital interfaces, the company fosters direct interaction with consumers, enhancing customer engagement and opening new revenue avenues. In essence, Jointown's prowess lies in its ability to integrate traditional distribution methods with innovative digital solutions, ensuring the company’s sustained growth and relevance in the ever-evolving pharmaceutical industry.
See Also
What is Jointown Pharmaceutical Group Co Ltd's Retained Earnings?
Retained Earnings
16.5B
CNY
Based on the financial report for Sep 30, 2025, Jointown Pharmaceutical Group Co Ltd's Retained Earnings amounts to 16.5B CNY.
What is Jointown Pharmaceutical Group Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
20%
Over the last year, the Retained Earnings growth was 12%. The average annual Retained Earnings growth rates for Jointown Pharmaceutical Group Co Ltd have been 9% over the past three years , 12% over the past five years , and 20% over the past ten years .